Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Keech

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Trials|June 21, 2019
Recruitment of men to a multi-centre diabetes prevention trial: an evaluation of traditional and online promotional strategiesKaren Bracken, Wendy Hague, Anthony Keech, et al.
Journal of the American Heart Association|October 25, 2024
Plasma Protein Biomarkers and Long-Term Cardiovascular Mortality Risk in Patients With Chronic Coronary Heart DiseaseRalph A H Stewart, Kristy P Robledo, Andrew M Tonkin, et al.
BMJ Paediatrics Open|February 12, 2025
Targeted oxygenation in the respiratory care of premature infants at delivery-effects on outcome: a randomised controlled trial (Torpido 3060) study protocolJu Lee Oei, Javeed Travadi, Adrienne Kirby, et al.
Journal of the American Heart Association|June 29, 2022
B-Type Natriuretic Peptide and Long-Term Cardiovascular Mortality in Patients With Coronary Heart DiseaseRalph A H Stewart, Adrienne Kirby, Harvey D White, et al.
JAMA Cardiology|November 9, 2017
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical TrialRobert P Giugliano, Anthony Keech, Sabina A Murphy, et al.
Clinical Cardiology|February 17, 2017
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trialRobert P Giugliano, Francois Mach, Kenton Zavitz, et al.
Resuscitation|May 14, 2025
Pre-hospital ECPR for refractory cardiac arrest - The PRECARE pilot feasibility studyNatalie Kruit, Brian Burns, Nicolas Shearer, et al.
NEJM Evidence|December 24, 2024
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with EvolocumabAndré Zimerman, Michelle L O'Donoghue, Xinhui Ran, et al.
Circulation|March 14, 2018
Inflammatory and Cholesterol Risk in the FOURIER TrialErin A Bohula, Robert P Giugliano, Lawrence A Leiter, et al.
Clinical Trials (London, England)|October 5, 2019
A high-volume, low-cost approach to participant screening and enrolment: Experiences from the T4DM diabetes prevention trialKaren Bracken, Anthony Keech, Wendy Hague, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Trials|June 21, 2019
Recruitment of men to a multi-centre diabetes prevention trial: an evaluation of traditional and online promotional strategiesKaren Bracken, Wendy Hague, Anthony Keech, et al.
Journal of the American Heart Association|October 25, 2024
Plasma Protein Biomarkers and Long-Term Cardiovascular Mortality Risk in Patients With Chronic Coronary Heart DiseaseRalph A H Stewart, Kristy P Robledo, Andrew M Tonkin, et al.
BMJ Paediatrics Open|February 12, 2025
Targeted oxygenation in the respiratory care of premature infants at delivery-effects on outcome: a randomised controlled trial (Torpido 3060) study protocolJu Lee Oei, Javeed Travadi, Adrienne Kirby, et al.
Journal of the American Heart Association|June 29, 2022
B-Type Natriuretic Peptide and Long-Term Cardiovascular Mortality in Patients With Coronary Heart DiseaseRalph A H Stewart, Adrienne Kirby, Harvey D White, et al.
JAMA Cardiology|November 9, 2017
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical TrialRobert P Giugliano, Anthony Keech, Sabina A Murphy, et al.
Clinical Cardiology|February 17, 2017
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trialRobert P Giugliano, Francois Mach, Kenton Zavitz, et al.
Resuscitation|May 14, 2025
Pre-hospital ECPR for refractory cardiac arrest - The PRECARE pilot feasibility studyNatalie Kruit, Brian Burns, Nicolas Shearer, et al.
NEJM Evidence|December 24, 2024
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with EvolocumabAndré Zimerman, Michelle L O'Donoghue, Xinhui Ran, et al.
Circulation|March 14, 2018
Inflammatory and Cholesterol Risk in the FOURIER TrialErin A Bohula, Robert P Giugliano, Lawrence A Leiter, et al.
Clinical Trials (London, England)|October 5, 2019
A high-volume, low-cost approach to participant screening and enrolment: Experiences from the T4DM diabetes prevention trialKaren Bracken, Anthony Keech, Wendy Hague, et al.
Pageof 10